While there are no specific clinical trials targeting GFPT2 in the context of paclitaxel resistance in ovarian cancer, ongoing clinical trials explore the role of NF-κB inhibitors in various cancer treatments [27]. This evidence concerns the gene NFKB1 and cancer.